External validation of the modified Glasgow prognostic score for renal cancer
Authors:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Medknow in Indian Journal of Urology
- Vol. 30 (1) , 33-7
Abstract
Purpose: The modified Glasgow prognostic Score (mGPS) incorporates C-reactive protein and albumin as a clinically useful marker of tumor behavior. The ability of the mGPS to predict metastasis in localized renal cell carcinoma (RCC) remains unknown in an external validation cohort. Patients and Methods: Patients with clinically localized clear cell RCC were followed for 1 year post-operatively. Metastases were identified radiologically. Patients were categorized by mGPS score as low-risk (mGPS = 0 points), intermediate-risk (mGPS = 1 point) and high-risk (mGPS = 2 points). Univariate, Kaplan-Meier and multivariate Cox regression analyses examined Recurrence -free survival (RFS) across patient and disease characteristics. Results: Of the 129 patients in this study, 23.3% developed metastases. Of low, intermediate and high risk patients, 10.1%, 38.9% and 89.9% recurred during the study. After accounting for various patient and tumor characteristics in multivariate analysis including stage and grade, only mGPS was significantly associated with RFS. Compared with low-risk patients, intermediate- and high-risk patients experienced a 4-fold (hazard ratios [HR]: 4.035, 95% confidence interval [CI]: 1.312-12.415, P = 0.015) and 7-fold (HR: 7.012, 95% CI: 2.126-23.123 P < 0.001) risk of metastasis, respectively. Conclusions: mGPS is a robust predictor of metastasis following potentially curative nephrectomy for localized RCC. Clinicians may consider mGPS as an adjunct to identify high-risk patients for possible enrollment into clinical trials or for patient counselingKeywords
This publication has 34 references indexed in Scilit:
- C-Reactive Protein as a Clinically Useful Biomarker of Metastasis of Renal Cell CarcinomaMolecular Diagnosis & Therapy, 2010
- Development and External Validation of a New Outcome Prediction Model for Patients With Clear Cell Renal Cell Carcinoma Treated With Nephrectomy Based on Preoperative Serum C-Reactive Protein and TNM Classification: The TNM-C ScoreJournal of Urology, 2009
- The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancerBJU International, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Prognostic markers in renal cell carcinomaCurrent Opinion in Urology, 2007
- C‐reactive protein is an informative predictor of renal cell carcinoma‐specific mortalityCancer, 2007
- Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissueKidney International, 2005
- RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPYJournal of Urology, 2005
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrologic Clinics of North America, 2003
- Incidental renal cell carcinoma—age and stage characterization and clinical implications: study of 1092 patients (1982–1997)Urology, 2000